Evidence map›Paper›PMID 42252358›Full record

SynthesisAnnals of surgical oncology2026

A Decade Later: An Updated Systematic Review and Meta-analysis of Overall Survival, Disease-Free Survival, Local Recurrence, and Nipple-Areolar Recurrence Following Nipple-Sparing Mastectomy.

Rachel N Rohrich, Hannah Soltani, Isabel Snee, Kenneth L Fan, Beth-Ann Lesnikoski, Lucy M De La Cruz

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rachel N RohrichDepartment of Plastic and Reconstructive Surgery, Medstar Georgetown University Hospital, Washington, DC, USA.
Hannah SoltaniDepartment of Plastic and Reconstructive Surgery, Medstar Georgetown University Hospital, Washington, DC, USA. Hannah.soltani@medstar.net.
Isabel SneeGeorgetown University School of Medicine, Washington, DC, USA.
Kenneth L FanDepartment of Plastic and Reconstructive Surgery, Medstar Georgetown University Hospital, Washington, DC, USA.
Beth-Ann LesnikoskiHCA Florida Palm Beach Breast Surgery, Loxahatchee, FL, USA.
Lucy M De La CruzDepartment of Breast Surgery, Medstar Georgetown University Hospital, Washington, DC, USA. Lucy.DeLaCruz@medstar.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSince our 2015 manuscript, nipple-sparing mastectomy (NSM) has been increasingly adopted in breast cancer management, though concerns regarding long-term oncologic safety persist. We provide a 10-year update on oncologic outcomes following NSM, including overall survival (OS), disease-free survival (DFS), local recurrence (LR), and nipple-areolar complex recurrence (NACR). PATIENTS AND

methodsA Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-compliant systematic review identified studies reporting oncologic outcomes after NSM. Studies with internal comparison arms evaluating therapeutic NSM versus skin-sparing mastectomy (SSM) and/or modified radical mastectomy (MRM) were included in the meta-analysis. Studies lacking comparison arms were included in pooled analyses for NSM outcomes using a random-effects model. Weighted averages and 95% confidence intervals (CI) were calculated, and studies were stratified by duration of follow-up.

resultsA total of 60 studies comprising 7752 NSM patients were included: 11 studies had comparison arms; 9 studies reporting OS demonstrated a significant pooled risk difference of 2.1% favoring NSM over MRM/SSM (95% CI 0.0-4.3%, p = 0.047); 7 studies reporting DFS showed a nonsignificant pooled risk difference of 4.8% favoring NSM (95% CI -0.8 to 10.3%, p = 0.093); 11 studies reporting LR demonstrated a nonsignificant pooled risk difference of -0.7% (95% CI -2.1 to 0.8%, p = 0.35). The systematic review included all 60 studies. Weighted average follow-up ranged from 25.6 to 133.4 months across groups. Among patients with 10 years of follow-up (n = 391), OS was 82.0% (80.9-93.2%), DFS 60.7% (58.8-62.7%), LR 15.1% (13.9-16.2%), and NACR 1.1% (1.0-1.1%).

conclusionsNSM is associated with excellent long-term survival and low recurrence rates comparable to SSM/MRM, with minimal NAC recurrence in appropriately selected patients, supporting its long-term oncologic safety.

Indexed as

Breast NeoplasmsMastectomyNeoplasm Recurrence, LocalNipplesOrgan Sparing TreatmentsDisease-Free SurvivalFemaleHumansPrognosisSurvival RateBreast cancer managementMeta-analysisNipple-sparing mastectomyOncologic safetySystematic review

Identifiers

PMID42252358

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.